Navigation Links
Echo Therapeutics Announces Third Quarter 2012 Financial Results

PHILADELPHIA, Nov. 8, 2012 /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced its financial results for the quarter ended September 30, 2012. Echo's Quarterly Report on Form 10-Q, as filed with the SEC, will be available by visiting the Investors section of Echo's website at

(Logo: )

Recent Corporate Highlights

  • In preparation for its planned first quarter 2013 ISO audit, Echo made substantial advances towards finalizing its quality management systems.  ISO certification is a key step towards achieving compliance with European regulatory requirements.
  • Echo initiated the process of conducting clinical studies at investigational sites in Europe and the U.S. to support CE Mark and other commercialization efforts.
  • Echo hired key development, product, and clinical personnel to prepare for and accelerate its plans for Symphony's European and U.S. regulatory clearance and commercialization.
  • "We had a very productive third quarter, with significant progress made towards the Company's clinical, development and regulatory objectives needed to commercialize our Symphony system," commented Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics.  "As we look toward 2013, we remain focused on obtaining European clearance of Symphony and its commercial launch, as well as initiating our pivotal studies to support PMA submission in the U.S."

    Third Quarter 2012 Financial Results
    Echo's net loss for the third quarter of 2012 was $4.3 million, or $0.11 per share, compared to $1.5 million, or $0.04 per share, for the third quarter of 2011.  The operating loss for the third quarter of 2012 was $3.6 million compared to $2.3 million for the third quarter of 2011.  Research and development expenses were $2.1 million for the third quarter of 2012 compared to $0.7 million for the third quarter of 2011.  The increase in research and development expenses was primarily related to increased development, regulatory and clinical expenses, as well as manufacturing preparation costs.  General and administration expenses were flat from period to period and attributable to personnel and facility costs, as well as legal and other public company expenses. 

    Echo reported a cash balance of approximately $1.4 million as of September 30, 2012.  In August of 2012, Echo's financial position was augmented by a $20 million credit facility with Platinum-Montaur Life Sciences, LLC.  To date, Echo has received $3 million in cash proceeds from that facility. 

    Conference Call
    Management will host a conference call today starting at 9:00 AM EST.  To listen in and/or participate in the call, please dial 877.317.6789 and reference the conference number 10020170.  The archived audiocast will be available for fourteen days following the call by visiting the Events section of Echo's website at

    About Echo Therapeutics
    Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system.  Our target is patients who could benefit from glucose monitoring in the hospital setting, including critical care.  Significant opportunity also exists for patients with diabetes to use Symphony in the outpatient setting.  Echo is also developing its needle-free skin preparation component of Symphony, the Prelude® SkinPrep System, as a platform technology to enhance drug delivery of topical pharmaceuticals.

    Cautionary Statement Regarding Forward Looking Statements
    The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo's ongoing studies, including the safety and efficacy of Echo's Symphony tCGM System, the failure of future development and preliminary marketing efforts related to Echo's Symphony tCGM and Prelude SkinPrep Systems, Echo's ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo's and its partners' ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo's filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2011, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

    For More Information:
    Christine H. Olimpio
    Director, Investor Relations and Corporate Communications
    (215) 717-4104Connect With Us:
    - Visit our website at
    - Follow us on Twitter at
    - Join us on Facebook at

     Echo Therapeutics, IncCondensed Consolidated Balance Sheets September 30,2012December 31,2011ASSETSCurrent Assets:Cash and cash equivalents

    8,995,571Current portion of deferred financing costs

    1,068,462-Prepaid expenses, cash restricted pursuant to letters of credit

     and other current assets

    482,172567,940Total current assets

    2,946,4749,563,511Net property and equipment (including assets under capitalized leases)

    1,205,845317,731Other Assets:Intangible assets, net of accumulated amortization

    9,625,0009,625,000Deferred financing costs

    3,791,329-Other assets

    10,56620,565Total other assets

    13,426,8959,645,565Total assets

    9,526,807LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts payable

    365,298Deferred revenue from licensing arrangements

    92,794123,708Derivative warrant liability

    6,772,5361,035,337Accrued expenses and other liabilities

    1,315,930968,120Total current liabilities

    9,210,7482,492,463Note payable, net of discount and capital lease obligation, net of current portion

    7,57365,755Total liabilities

    9,218,3212,558,218CommitmentsStockholders' Equity:Convertible preferred stock, Series C & D

    30,16030,160Common stock

    399,116385,442Additional paid-in capital

    99,906,83398,116,327Common stock subscribed for but not paid for or issued

    -6,667Accumulated deficit

    (91,975,216)(81,570,007)Total stockholders' equity

    8,360,89316,968,589Total liabilities and stockholders' equity




    Condensed Consolidated Statements of Operations Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2012201120122011Licensing revenue

    98,550Other revenue

    ---145,152Total revenues

    30,927(44,360)92,781343,702Operating Expenses:Research and development

    2,139,465695,0195,731,4172,557,118Selling, general and administrative

    1,508,0691,527,3174,702,3253,427,582Total operating expenses

    3,647,5342,222,33610,433,7425,984,700Loss from operations

    (3,616,607)(2,266,696)(10,340,961)(5,640,998)Other Income (Expense):Interest income (expense), net

    (88,488)196(84,257)(9,869)Debt financing costs

    (160,000)-(160,000)-Loss on extinguishment of debt/payables

    ---(1,514)Gain (loss) on disposals of assets

    --(21,272)834Gain (loss) on revaluation of derivative warrant liability

    (400,000)893,229201,281(2,258,679)Other income (expense), net

    (648,488)893,425(64,248)(2,269,228)Net loss

    (4,265,095)(1,373,271)(10,405,209)(7,910,226)Deemed dividend on repricing of warrants

    -(87,500)-(87,500)Accretion of dividends on Convertible Perpetual
    Redeemable Preferred Stock

    -(49,519)-(142,761)Deemed dividend on beneficial conversion feature of
    Series D Convertible Preferred Stock

    ---(1,975,211)Net loss applicable to common shareholders

    (1,510,290)$   (10,405,209)$   (10,115,698)Net loss per common share, basic and diluted

    (0.30)Basic and diluted weighted average common shares



    SOURCE Echo Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
    2. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
    3. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
    4. Novelos Therapeutics Closes $2 Million Private Placement
    5. US Allows Two Key Patents for Silence Therapeutics
    6. United Therapeutics Corporation Reports Third Quarter 2012 Financial Results
    7. Cell Therapeutics, Inc. (CTI) Reduces Net Loss for Third Quarter and Nine Months Ended September 30, 2012 Compared to Same Periods in 2011
    8. Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-targeted PET Imaging Agent at UW Carbone Cancer Center
    9. United Therapeutics Announces Collaboration With Ascendis Pharma To Develop Self-Injectable Treprostinil For Pulmonary Arterial Hypertension
    10. Mersana Therapeutics Named a "Fierce 15" Biotech Company for 2012
    11. Cell Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Rule
    Post Your Comments:
    (Date:11/26/2015)... , November 26, 2015 3D ... by 2022, according to a new report by Grand View ... Kidney Disease (CKD) which demands kidney transplantation is expected to ... cost effective substitute for organ transplantation. --> 3D ... by 2022, according to a new report by Grand View ...
    (Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
    (Date:11/26/2015)... November 26, 2015 ... adds "Global Repaglinide Industry ... Report on China Repaglinide Market, 2010-2019" ... data and information to its online ... . --> ...
    Breaking Medicine Technology:
    (Date:11/25/2015)... ... 2015 , ... Beddit® has launched a new Android app for ... features a more intuitive SleepScore™ that rates sleep quality on a 100-point scale and ... created by a proprietary algorithm. Beddit analyzes the data to provide an easy to ...
    (Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... In an ... Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of ... and surgical intensive care units (totaling 30 beds) from May 2014 through October 2015 ...
    (Date:11/25/2015)... ... ... Today, Mothers Against Drunk Driving (MADD) learned that the number of ... time since 2011. In 2014, there were 9,967 fatalities involving an alcohol impaired driver, ... Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in 2014. Drunk ...
    (Date:11/25/2015)... Silver Spring, Md (PRWEB) , ... November 25, ... ... the Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups ... the history of this disease. The Periwinkle Pioneers, nominated by the public, will ...
    (Date:11/25/2015)... , ... November 25, 2015 , ... ... announced that it has undertaken significant expansion of its current state of the ... is part of PharmaTech’s strategy to increase its manufacturing capacity as well as ...
    Breaking Medicine News(10 mins):